Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

HUTCHMED (LSE:HCM): SAFFRON phase III shows ORPATHYS plus TAGRISSO extends median overall survival to 17.8 months versus 12.9 on chemotherapy

HUTCHMED (China) Limited (LSE:HCM) said on 26 October 2026 that detailed SAFFRON data were presented in Presidential Symposium II at the ESMO Congress 2026 in Madrid, as abstract LBA6, on 25 October. The results were simultaneously published in The New England Journal of Medicine.

Ankur Sharma | 27 October 2026

PureTech Health (LSE:PRTC) unit Gallop reports 45.5% response rate for LYT-200 combination in phase 1b blood cancer data at ESMO

PureTech Health plc (LSE:PRTC) said on 26 October 2026 that Gallop Oncology, a PureTech Founded Entity that PureTech founded and wholly owns, presented phase 1b results for LYT-200 at the ESMO Congress 2026 in Madrid. The data were presented in an oral session by …

Ankur Sharma | 27 October 2026

Avacta (LSE:AVCT) reports 11.4-month median PFS for faridoxorubicin in salivary gland cancer, nearly double historical benchmark

Avacta Group plc (LSE:AVCT), which trades as Avacta Therapeutics, released updated data on 26 October 2026 from its ongoing phase 1a/1b trial of faridoxorubicin (AVA6000) in salivary gland cancer (SGC). The results were presented as poster 1549P at the European Society for Medical Oncology …

Ankur Sharma | 27 October 2026

HUTCHMED (LSE:HCM): SANOVO phase III shows ORPATHYS plus TAGRISSO lifts first-line median PFS to 24.9 months from 13.8 months

HUTCHMED (LSE:HCM) (China) Limited said on 26 October 2026 that full results from SANOVO were presented that morning at 08:30 CET in a Proffered Paper session at the ESMO Congress 2026 in Madrid, as abstract LBA69. The presentation followed the SAFFRON phase III data, …

Ankur Sharma | 27 October 2026

GSK (LSE:GSK): Ris-Rez cuts risk of progression or death by 67% versus chemotherapy in phase III osteosarcoma trial in China

GSK plc (LSE:GSK) said on 26 October 2026 that ARTEMIS-011, a pivotal phase III, multicentre, randomised, open-label trial in China, met its primary endpoint. The trial tested risvutatug rezetecan, known as Ris-Rez, an investigational antibody-drug conjugate targeting B7-H3, in patients with relapsed or progressed …

Ankur Sharma | 27 October 2026

GSK (LSE:GSK): Jemperli AZUR-1 data show 76% complete response rate in MSI-H/dMMR rectal cancer

GSK plc (LSE:GSK) has released updated results from AZUR-1, a global, open-label, single-arm, registrational phase II trial of Jemperli (dostarlimab) monotherapy in adults with previously untreated stage II and III mismatch repair deficient or microsatellite instability-high (MSI-H/dMMR) locally advanced rectal cancer. The data were …

Ankur Sharma | 27 October 2026

GSK (LSE:GSK) reports 62% confirmed response rate for Mo-Rez in phase Ib platinum-resistant ovarian cancer data

GSK plc (LSE:GSK) has presented updated data for mocertatug rezetecan, known as Mo-Rez, in patients with platinum-resistant ovarian cancer (PROC). The results were shown in a late-breaking oral session at the ESMO Congress 2026 in Madrid. The release was issued on 23 October 2026 …

Ankur Sharma | 27 October 2026

Cizzle Biotechnology (LSE:CIZ) secures £500,000 subscription at 0.8p and converts £250,000 of loan notes

On Monday 26 October 2026, Cizzle Biotechnology Holdings plc (LSE:CIZ) (CIZ), whose shares trade on the Main Market of the London Stock Exchange, announced a direct subscription to raise £500,000 before expenses. The release was headlined "£500,000 Subscription, conversion of loan notes". The sole …

Ankur Sharma | 27 October 2026

Oxford BioDynamics Plc (LSE:OBD): Why This London-Listed Stock Is Drawing Attention on 27 October 2026

The business case for Oxford BioDynamics Plc (LSE:OBD) rests on execution rather than on its market quotation alone. Investors need to distinguish the addressable market from revenue that can realistically be captured, and distinguish an announced opportunity from a signed, profitable contract. Operating leverage …

Ankur Sharma | 27 October 2026

Shield Therapeutics Plc (LSE:STX): Why This London-Listed Stock Is Drawing Attention on 27 October 2026

The business case for Shield Therapeutics Plc (LSE:STX) rests on execution rather than on its market quotation alone. Investors need to distinguish the addressable market from revenue that can realistically be captured, and distinguish an announced opportunity from a signed, profitable contract. Operating leverage …

Ankur Sharma | 27 October 2026
Support

Hi! How can we help you today?

Loading…